Watchlist Price Alert

Immunovant Inc. (IMVT)

NASDAQ: IMVT · Real-Time Price · USD

15.81

-0.05 (-0.32%)

At close: Jun 20, 2025, 3:59 PM

15.80

-0.06%

After-hours: Jun 20, 2025, 05:04 PM EDT

-0.32% (1D)

Bid	15.5
Market Cap	2.7B
Revenue (ttm)	160K
Net Income (ttm)	-413.84M
EPS (ttm)	-2.73
PE Ratio (ttm)	-5.79
Forward PE	-5.54
Analyst	Buy

Ask	16.2
Volume	656,770
Avg. Volume (20D)	1,638,143
Open	16.04
Previous Close	15.86
Day's Range	15.44 - 16.04
52-Week Range	12.72 - 34.47
Beta	0.61

About IMVT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol IMVT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for IMVT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

+5.6%

Immunovant shares are trading higher following a Q... Unlock content with Pro Subscription

3 months ago

+4.29%

Immunovant shares are trading higher. B of A Securities and Guggenheim reiterated Buy ratings on the stock.

News

2 weeks ago · zacks.com

Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?

Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 weeks ago · zacks.com

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus

Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

1 month ago · businesswire.com

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces an investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ: IMVT) and R...

3 months ago · zacks.com

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success

Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.